AP NEWS

First Patients in the Middle East Treated with Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

January 16, 2019

ST. PAUL, Minn.--(BUSINESS WIRE)--Jan 16, 2019--Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced today that the first patients in the United Arab Emirates (UAE) have been treated with its Diamondback 360 ® Coronary Orbital Atherectomy System (OAS).

The first UAE patients were treated by Professor Aref Nooryani, Chief Executive Officer and Head of the Al Qassimi Hospital Cardiac Center, Sharjah, UAE.

Professor Nooryani said, “Patients with calcific coronary artery disease have poor clinical outcomes. Until today, these patients presented a difficult challenge due to the limitations of the other therapies available to me. CSI’s unique orbital atherectomy technology enables effective modification of calcified lesions. The availability of the Diamondback 360 ® OAS in the UAE provides physicians, like me, with a minimally-invasive treatment option for a complex patient population.”

Scott Ward, Chairman, President and Chief Executive Officer of CSI, said, “In six months since we announced our international distribution partnership with OrbusNeich, we have successfully introduced OAS technology in Asia, Europe and the Middle East. Together we are demonstrating that the combination of OrbusNeich’s large international sales channel supported by CSI’s physician training and education will allow us to treat an increasing number of patients suffering from peripheral and coronary artery disease.”

In July 2018, CSI announced that it had signed an exclusive international distribution agreement with OrbusNeich to sell its coronary and peripheral OAS outside of the United States and Japan.

About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s OAS treat calcified and fibrotic plaque in arterial vessels throughout the leg and heart in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback Orbital Atherectomy System in peripheral arteries in August 2007. In October 2013, the company received FDA approval for the use of the Diamondback Orbital Atherectomy System in coronary arteries. The Stealth 360 ®  Peripheral Orbital Atherectomy System (OAS) received CE Mark in October 2014. Over 400,000 of CSI’s devices have been sold to leading institutions worldwide.

About OrbusNeich OrbusNeich ® is a global pioneer in the provision of life-changing vascular solutions and offers an extensive portfolio of products that set industry benchmarks in vascular intervention. Current products include the world’s first dual therapy stents, the COMBO ® Plus and COMBO ® Dual Therapy Stents, together with stents and balloons marketed under the names of Azule ®, Scoreflex ®, Sapphire ® II, Sapphire ® II PRO and Sapphire ® II NC, as well as products to treat peripheral artery disease: the Jade ® and Scoreflex ® PTA balloons. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Florida, USA; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to physicians in more than 60 countries. For more information, visit www.OrbusNeich.com.

Safe Harbor Certain statements in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this press release regarding anticipated future introduction of CSI devices outside of the United States and Japan; and the opportunity relating to these international sales, are forward-looking statements. These statements involve risks and uncertainties that could cause results to differ materially from those projected, including, but not limited to, regulatory developments, clearances and approvals; approval of our products for distribution in countries outside of the United States; approval of our products for reimbursement in and the level of reimbursement; the ability of OrbusNeich to successfully launch CSI products outside of the United States and Japan; the experience of physicians regarding the effectiveness and reliability of CSI’s products; the reluctance of physicians, hospitals and other organizations to accept new products; the impact of competitive products and pricing; general economic conditions; international trade developments; and other factors detailed from time to time in CSI’s SEC reports, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this release. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI’s actual results may differ materially from the expected results discussed in the forward-looking statements contained in this release. The forward-looking statements made in this release are made only as of the date of this release, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

Diamondback 360 ® Coronary Orbital Atherectomy Systems Indications:  The Diamondback 360 Coronary Orbital Atherectomy Systems (OAS) are percutaneous orbital atherectomy systems indicated to facilitate stent delivery in patients with coronary artery disease (CAD) who are acceptable candidates for PTCA or stenting due to  de novo, severely calcified coronary artery lesions.

Contraindications:  The OAS are contraindicated when the ViperWire ® guide wire cannot pass across the coronary lesion or the target lesion is within a bypass graft or stent. The OAS are contraindicated when the patient is not an appropriate candidate for bypass surgery, angioplasty, or atherectomy therapy, or has angiographic evidence of thrombus, or has only one open vessel, or has angiographic evidence of significant dissection at the treatment site and for women who are pregnant or children.

Warnings/Precautions:  Performing treatment in excessively tortuous vessels or bifurcations may result in vessel damage; The OAS was only evaluated in severely calcified lesions; A temporary pacing lead may be necessary when treating lesions in the right coronary and circumflex arteries; On-site surgical back-up should be included as a clinical consideration; Use in patients with an ejection fraction (EF) of less than 25% has not been evaluated. See the instructions for use before performing Diamondback 360 ®   Coronary OAS procedures for detailed information regarding the procedure, indications, contraindications, warnings, precautions, and potential adverse events. For further information call CSI at 1-877-274-0901 and/or consult CSI’s website at  www.csi360.com.

Caution:  Federal law (USA) restricts this device to sale by or on the order of a physician.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190116005779/en/

CONTACT: Cardiovascular Systems, Inc.

Jack Nielsen

(651) 202-4919

j.nielsen@csi360.comPadilla:

Matt Sullivan

(612) 455-1709

matt.sullivan@padillaco.com

KEYWORD: UNITED STATES NORTH AMERICA MINNESOTA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CARDIOLOGY MEDICAL DEVICES PROFESSIONAL SERVICES FINANCE GENERAL HEALTH

SOURCE: Cardiovascular Systems, Inc.

Copyright Business Wire 2019.

PUB: 01/16/2019 04:05 PM/DISC: 01/16/2019 04:05 PM

http://www.businesswire.com/news/home/20190116005779/en

AP RADIO
Update hourly